JP2006523704A - ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター - Google Patents
ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター Download PDFInfo
- Publication number
- JP2006523704A JP2006523704A JP2006510018A JP2006510018A JP2006523704A JP 2006523704 A JP2006523704 A JP 2006523704A JP 2006510018 A JP2006510018 A JP 2006510018A JP 2006510018 A JP2006510018 A JP 2006510018A JP 2006523704 A JP2006523704 A JP 2006523704A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- substituted
- substituents
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*C(C*(C(CC1)CC1(*)C(*1Cc2cc(*)ccc2CC1)=O)*(C)C*(C)C1)C1I(C)* Chemical compound C*C(C*(C(CC1)CC1(*)C(*1Cc2cc(*)ccc2CC1)=O)*(C)C*(C)C1)C1I(C)* 0.000 description 21
- DIQOUXNTSMWQSA-UHFFFAOYSA-N C1C2OCC1NC2 Chemical compound C1C2OCC1NC2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- VDFRMZDFOGAEPN-UHFFFAOYSA-N CC(C)C(CC1)(CC1=O)C(N1Cc2cc(C(F)(F)F)ccc2CC1)=O Chemical compound CC(C)C(CC1)(CC1=O)C(N1Cc2cc(C(F)(F)F)ccc2CC1)=O VDFRMZDFOGAEPN-UHFFFAOYSA-N 0.000 description 1
- ZCNCSILJDDZRKG-UHFFFAOYSA-N CC(C)C(CC1)(CC1N1C(CNc2c(C)cccc2)C(C2)C2C1)C(N(CC1)Cc2c1ccc(C(F)(F)F)c2)=O Chemical compound CC(C)C(CC1)(CC1N1C(CNc2c(C)cccc2)C(C2)C2C1)C(N(CC1)Cc2c1ccc(C(F)(F)F)c2)=O ZCNCSILJDDZRKG-UHFFFAOYSA-N 0.000 description 1
- ZCQSCOJTSLTROH-AZUAARDMSA-N CC(C)[C@@](CC1)(C[C@H]1N(CC1)CCC1c(cc1)ccc1F)C(O)=O Chemical compound CC(C)[C@@](CC1)(C[C@H]1N(CC1)CCC1c(cc1)ccc1F)C(O)=O ZCQSCOJTSLTROH-AZUAARDMSA-N 0.000 description 1
- URZVRNBNUQBLCK-VIFPVBQESA-N CC(C)[C@](CC1)(CC1=O)C(O)=O Chemical compound CC(C)[C@](CC1)(CC1=O)C(O)=O URZVRNBNUQBLCK-VIFPVBQESA-N 0.000 description 1
- QEHHUSHZNZKZPQ-YYSXCIBHSA-N CC(C)[C@](CC1)(CC1N(CC1)CC(C)C1c1cccc(C(O)=O)c1)C(N(CC1)Cc2c1ccc(C(F)(F)F)c2)=O Chemical compound CC(C)[C@](CC1)(CC1N(CC1)CC(C)C1c1cccc(C(O)=O)c1)C(N(CC1)Cc2c1ccc(C(F)(F)F)c2)=O QEHHUSHZNZKZPQ-YYSXCIBHSA-N 0.000 description 1
- ZURSYFJYWOFDLX-ZYZRXSCRSA-N CC(C)[C@](CC1)(CC1N1CCCC1)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O Chemical compound CC(C)[C@](CC1)(CC1N1CCCC1)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O ZURSYFJYWOFDLX-ZYZRXSCRSA-N 0.000 description 1
- ASQSOJZDTKSHFC-XGCAABAXSA-N CC(C)[C@](CC1)(CC1N1Cc(cccc2)c2OCC1)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O Chemical compound CC(C)[C@](CC1)(CC1N1Cc(cccc2)c2OCC1)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O ASQSOJZDTKSHFC-XGCAABAXSA-N 0.000 description 1
- ZCQSCOJTSLTROH-QUCCMNQESA-N CC(C)[C@](CC1)(C[C@@H]1N(CC1)CCC1c(cc1)ccc1F)C(O)=O Chemical compound CC(C)[C@](CC1)(C[C@@H]1N(CC1)CCC1c(cc1)ccc1F)C(O)=O ZCQSCOJTSLTROH-QUCCMNQESA-N 0.000 description 1
- QEHHUSHZNZKZPQ-DISVULIBSA-N CC(C)[C@](CC1)(C[C@@H]1N(CC1)C[C@@H](C)[C@@H]1c1cc(C(O)=O)ccc1)C(N(CC1)Cc2c1ccc(C(F)(F)F)c2)=O Chemical compound CC(C)[C@](CC1)(C[C@@H]1N(CC1)C[C@@H](C)[C@@H]1c1cc(C(O)=O)ccc1)C(N(CC1)Cc2c1ccc(C(F)(F)F)c2)=O QEHHUSHZNZKZPQ-DISVULIBSA-N 0.000 description 1
- XUIIHWKNDPMCIT-CJAUYULYSA-N CC(C)[C@](CC1)(C[C@@H]1NC(OC(C)(C)C)=O)C(N1Cc2cc(C(F)(F)F)cc(C(OC)=O)c2CC1)=O Chemical compound CC(C)[C@](CC1)(C[C@@H]1NC(OC(C)(C)C)=O)C(N1Cc2cc(C(F)(F)F)cc(C(OC)=O)c2CC1)=O XUIIHWKNDPMCIT-CJAUYULYSA-N 0.000 description 1
- WLXRZBCWGSHZAT-YGRLFVJLSA-N CC(C)[C@](CC1)(C[C@@H]1NC(OC(C)(C)C)=O)C(O)=O Chemical compound CC(C)[C@](CC1)(C[C@@H]1NC(OC(C)(C)C)=O)C(O)=O WLXRZBCWGSHZAT-YGRLFVJLSA-N 0.000 description 1
- UCPGHVGGKXXLPM-ABAIWWIYSA-N CC(C)[C@](CC1)(C[C@@H]1NC(OC(C)(C)C)=O)C(OC)=O Chemical compound CC(C)[C@](CC1)(C[C@@H]1NC(OC(C)(C)C)=O)C(OC)=O UCPGHVGGKXXLPM-ABAIWWIYSA-N 0.000 description 1
- IAXQQPKNKGUTNJ-CVDCTZTESA-N CC(C)[C@](CC1)(C[C@H]1N(CC1)CCC1C(O)=O)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O Chemical compound CC(C)[C@](CC1)(C[C@H]1N(CC1)CCC1C(O)=O)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O IAXQQPKNKGUTNJ-CVDCTZTESA-N 0.000 description 1
- OPBAFCTVMLQILR-UHFFFAOYSA-N CCOC(N(CC1)CCN1C(CC1)CC1(C(C)C)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O)=O Chemical compound CCOC(N(CC1)CCN1C(CC1)CC1(C(C)C)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O)=O OPBAFCTVMLQILR-UHFFFAOYSA-N 0.000 description 1
- FKVIXUFHAPLUEH-AWEZNQCLSA-N CCOC(c1cccc([C@@H](CCNC2)C2=C)c1)=O Chemical compound CCOC(c1cccc([C@@H](CCNC2)C2=C)c1)=O FKVIXUFHAPLUEH-AWEZNQCLSA-N 0.000 description 1
- PXDABBCZPZCHCC-SQHAQQRYSA-N COC[C@](CC1)(C[C@@H]1N(CC1)CCC1c(cc1)ccc1F)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O Chemical compound COC[C@](CC1)(C[C@@H]1N(CC1)CCC1c(cc1)ccc1F)C(N(CC1)Cc2c1ncc(C(F)(F)F)c2)=O PXDABBCZPZCHCC-SQHAQQRYSA-N 0.000 description 1
- NGQHLYGRTFVUEM-UHFFFAOYSA-N FC(c1cc(CNCC2)c2cc1)(F)F Chemical compound FC(c1cc(CNCC2)c2cc1)(F)F NGQHLYGRTFVUEM-UHFFFAOYSA-N 0.000 description 1
- YMCBRRKLOISKLI-RCZVLFRGSA-N O=C([C@@](CC1)(C[C@@H]1N(CC1)CCC1c1ccccc1)C(F)(F)F)N(CC1)Cc2c1ncc(C(F)(F)F)c2 Chemical compound O=C([C@@](CC1)(C[C@@H]1N(CC1)CCC1c1ccccc1)C(F)(F)F)N(CC1)Cc2c1ncc(C(F)(F)F)c2 YMCBRRKLOISKLI-RCZVLFRGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46367303P | 2003-04-17 | 2003-04-17 | |
| PCT/US2004/011463 WO2004094371A2 (en) | 2003-04-17 | 2004-04-14 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523704A true JP2006523704A (ja) | 2006-10-19 |
| JP2006523704A5 JP2006523704A5 (enExample) | 2007-05-10 |
Family
ID=33310806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006510018A Pending JP2006523704A (ja) | 2003-04-17 | 2004-04-14 | ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1622916A4 (enExample) |
| JP (1) | JP2006523704A (enExample) |
| CN (1) | CN100384856C (enExample) |
| AU (1) | AU2004232939A1 (enExample) |
| CA (1) | CA2521625A1 (enExample) |
| WO (1) | WO2004094371A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021512098A (ja) * | 2018-01-31 | 2021-05-13 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体修飾因子およびその使用 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004232939A1 (en) * | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| US7598243B2 (en) | 2003-04-17 | 2009-10-06 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| CA2649636A1 (en) * | 2006-04-20 | 2007-11-01 | F. Hoffmann-La Roche Ag | Diazepan derivatives modulators of chemokine receptors |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| SMT201700456T1 (it) | 2009-07-27 | 2017-11-15 | Gilead Sciences Inc | Composti eterociclici fusi come modulatori dei canali ionici |
| AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
| JP5858586B2 (ja) | 2010-07-02 | 2016-02-10 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| RS62809B1 (sr) | 2015-05-21 | 2022-02-28 | Chemocentryx Inc | Modulatori ccr2 |
| WO2018026763A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SG11201900554YA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda modulators and methods of using same |
| MX383650B (es) | 2016-08-01 | 2025-03-14 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| US11304952B2 (en) | 2017-09-25 | 2022-04-19 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| EP3737367B1 (en) | 2018-01-08 | 2024-10-02 | ChemoCentryx, Inc. | Ccr2 antagonists for the treatment of cutaneous t-cell lymphoma |
| CN111056955B (zh) * | 2019-12-16 | 2021-05-25 | 中国科学院大连化学物理研究所 | 一种环己烯制备己二胺的方法 |
| CN117342958B (zh) * | 2023-09-12 | 2025-12-16 | 武汉理工大学 | 一种埋底界面材料及其制备得到的柔性钙钛矿太阳能电池 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013824A1 (en) * | 2000-08-17 | 2002-02-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| JP2005532308A (ja) * | 2002-04-29 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤 |
| JP3780291B2 (ja) * | 2002-04-29 | 2006-05-31 | メルク エンド カムパニー インコーポレーテッド | テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004232939A1 (en) * | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
-
2004
- 2004-04-14 AU AU2004232939A patent/AU2004232939A1/en not_active Abandoned
- 2004-04-14 JP JP2006510018A patent/JP2006523704A/ja active Pending
- 2004-04-14 CN CNB2004800165371A patent/CN100384856C/zh not_active Expired - Fee Related
- 2004-04-14 WO PCT/US2004/011463 patent/WO2004094371A2/en not_active Ceased
- 2004-04-14 CA CA002521625A patent/CA2521625A1/en not_active Abandoned
- 2004-04-14 EP EP04750112A patent/EP1622916A4/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013824A1 (en) * | 2000-08-17 | 2002-02-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| JP2005532308A (ja) * | 2002-04-29 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤 |
| JP3780291B2 (ja) * | 2002-04-29 | 2006-05-31 | メルク エンド カムパニー インコーポレーテッド | テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021512098A (ja) * | 2018-01-31 | 2021-05-13 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体修飾因子およびその使用 |
| JP7210599B2 (ja) | 2018-01-31 | 2023-01-23 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体修飾因子およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1622916A4 (en) | 2008-11-05 |
| CA2521625A1 (en) | 2004-11-04 |
| EP1622916A2 (en) | 2006-02-08 |
| WO2004094371A2 (en) | 2004-11-04 |
| AU2004232939A1 (en) | 2004-11-04 |
| CN1805965A (zh) | 2006-07-19 |
| CN100384856C (zh) | 2008-04-30 |
| WO2004094371A3 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3780291B2 (ja) | テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤 | |
| JP4440257B2 (ja) | ケモカイン受容体のベンゾオキサジニル−アミドシクロペンチル−複素環式モジュレーター | |
| JP2006523704A (ja) | ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター | |
| AU2005257859A1 (en) | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | |
| JP2007519734A (ja) | アミノシクロペンチルピリドピラジノン系ケモカイン受容体活性調節剤 | |
| US7700772B2 (en) | Amino heterocyclic modulators of chemokine receptor activity | |
| US7566726B2 (en) | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity | |
| US7410961B2 (en) | 2,6-disubstituted piperiddines as modulators | |
| JP2007519633A (ja) | アルキルアミノ、アリールアミノおよびスルホンアミドシクロペンチルアミド系のケモカイン受容体活性調節剤 | |
| US20070238723A1 (en) | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | |
| US20060183731A1 (en) | 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity | |
| US7598243B2 (en) | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | |
| US7589085B2 (en) | Tetrahydropyran heterocyclic cyclopentyl heteroaryl modulators of chemokine receptor activity | |
| US20070299104A1 (en) | Tetrahydropyranyl Cyclopentyl 1-Substituted and 1,1-Disubstituted Tetrahydroisoquinoline Modulators of Chemokine Receptor Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100427 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100428 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101102 |